Patent ID: 11858995
Assignee: GENMAB A/S
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 24:
25. A method of treating chronic lymphocytic leukemia (CLL) in a human subject, the method comprising subcutaneously administering to the subject a bispecific antibody comprising:
a first heavy chain and a first light chain comprising the amino acid sequences set forth in SEQ ID NOs: 24 and 25, respectively, and a second heavy chain and a second light chain comprising the amino acid sequences set forth in SEQ ID NOs: 26 and 27, respectively, wherein the bispecific antibody is administered at a dose ranging from 12-60 mg in 28-day cycles, wherein:
a) in cycle 1, a priming dose of 0.16 mg is administered on day 1, an intermediate dose of 0.8 mg on day 8, and a full dose of 12-60 mg on days 15 and 22;
b) in cycles 2-3, a full dose of 12-60 mg is administered on days 1, 8, 15, and 22;
c) in cycles 4-9, a full dose of 12-60 mg is administered on days 1 and 15; and
d) in cycle 10 and subsequent cycles, a full dose of 12-60 mg is administered on day 1.